Global Next-Generation Antibody Therapeutics Market To Generate Revenue Worth $15,308.6 Million by 2030

The global next-generation antibody therapeutics market is projected to generate $15,308.6 million revenue by 2030, advancing at a CAGR of 11.8% during 2021–2030. This will be on account of the growing prevalence of chronic diseases, increasing R&D for improved products, snowballing healthcare expenditure, and technological progressions in antibody therapeutics.

Some of the major reasons leading to an increase in the number of chronic disease cases are unhealthy lifestyles, poor diet, and addictions, such as smoking. Compared to traditional antibodies, next-generation variants are more effective in the treatment of cancer, autoimmune disorders, and inflammatory diseases. This is attracting pharmaceutical and biotechnology companies to increase their investment in the R&D of advanced antibody therapeutics.

In addition, governments of various countries are making improvements in healthcare facilities and taking initiatives to offer affordable next-generation antibody therapeutics. The increasing global GDP and growing healthcare expenditure have impacted the next-generation antibody therapeutics market growth positively. Moreover, the use of advanced technologies, such as antibody–drug conjugates, glycoengineered antibodies, and bispecific antibodies (BsAbs), has resulted in the development of antibody therapeutics with improved characteristics.

Oncology Category Leads Market

The oncology category accounted for the largest revenue share, around 80%, in 2021, and the same is expected to grow at the highest CAGR, of around 13%, during 2021–2030. This is attributed to the rising number of cancer cases all over the world. In recent times, there has been an increase in the adoption of monoclonal antibodies for the treatment of hematologic malignancies and solid tumors. The rising number of drug approvals, as well as the robust drug pipeline, are driving the category growth.

ADCs Category Leads Market

The ADCs category held the largest share in 2021, propelled by the increasing use of such therapy in breast cancer treatment and surging adoption of the cleavable linker technology in commercial ADC products.

APAC To Record Highest CAGR in Market

The APAC market is expected to witness the highest CAGR, of around 13%, in the forecast period, on account of the rising number of efforts by global firms to penetrate the emerging APAC market. In addition, the presence of a large number of prominent players in the region and the rising number of national as well as international collaborations amongst them are driving the market growth. Furthermore, the surging adoption of biosimilars in the region is expected to offer lucrative opportunities for the regional market growth.

The major players operating in the global next-generation antibody therapeutics market are F. Hoffmann-La Roche Ltd., Kyowa Kirin Co. Ltd., Seagen Inc., ImmunoGen Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Pfizer Inc., Catalent Inc., AstraZeneca plc, and Xencor Inc.